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Abstract
In this work we investigate the use of nanoporous carrier as drug delivery
systems for hydrophobic molecules. By studying a model system made of
porous silicon loaded with β-carotene, we unveil a fundamental limitation of
these carriers that is due to heterogeneous nucleation that imposes a trade-
off between the amount of drug loaded and the reproducibility of the release.
Nonetheless, such issue is an alternative and improved method, compared
with the standard induction time, to monitor the formation of heterogenously
nucleated aggregates.
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heterogeneous nucleation
1. Introduction
Large amount of newly developed drugs are composed of poorly water
soluble molecules [1]. This fact causes a growing interest in developing drug
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delivery systems (DDS) able to handle poorly soluble compounds and, possi-
bly, to protect them from degradation. Nanoporous inorganic carriers offers
several advantages as they load large amount of drug and are (often) chem-
ically inert. Yet, the release of hydrophobic molecules from such carriers
has to cope with interfacial processes that can heavily impact their perfor-
mance. Here we investigate a model system made by porous silicon (PSi)
loaded with a highly lipophilic molecule (β-carotene, BCAR) and we discuss
the general limitations induced by heterogeneous nucleation (HN) on release
reproducibility.
BCAR has been chosen for its highly apolar nature (its solubility in water
is 0.6 mg/L at 25◦C), its easy oxidation -which permits to detect ”subtle”
chemical reactions taking place within PSi carriers- and its high optical ab-
sorbance -which allows its quantification down to nmol concentration.
PSi possesses several attractive characteristics that render it a material of
interest as DDS [2, 3, 4]: its chemistry is well known [5], it is biocompatible
and biodegradable [6] and it can be used as luminescent (tagged) carrier to
track its fate once injected inside organisms [7].
PSi might even protects delicate cargo, in fact: 1) its high absorbtion coeffi-
cient in the UV-vis range shields the drug from photochemical reactions; 2)
as-prepared PSi surface easily undergoes oxidization reactions, thus it can
acts as sacrificial material to protect readily oxidized drugs; 3) the exchange
of reactive gases (e.g. oxygen) is partially slowed down within the nanopores,
thus a reduced amount of environmental active species is able to reach and
degrade the loaded compounds.
Shielding properties of PSi are already demonstrated [8, 9, 10] for specific
2
molecules, but we highlight that its supposed chemical stability needs to be
carefully evaluated, since PSi might stimulate slow chemical reactions mak-
ing this material unsuitable for drug storage.
Artificial surfaces with well controlled size and shape have been used to in-
duce the HN of specific polymorphs [11, 12, 13, 14], but HN remains poorly
investigated on nanoporous systems with random topography because of the
difficulties in studying such irreproducible phenomena [15].
HN is commonly investigated using the induction method [16] that poses
formidable experimental issues in the case of HN on solid surfaces, as the
definition of induction time depends on the spatial resolution achievable to
check the presence of nuclei.
In this work we characterize fundamental interactions that take place be-
tween nanoporous carriers and hydrophobic molecules and we highlight the
requirement of long term stability studies to prove the storage capability
of inorganic, supposed inert, materials. Furthermore we underline a strong
effect due to HN that induces the formation of slowly soluble aggregates,
which, in turn, make the release kinetics irreproducible. This fact has to be
considered during the design of porous carriers, otherwise it would rule out
one of their main advantage that is their large loading capacity. Finally we
propose such irreproducibility to be used as an alternative and more sensi-
tive method, compared to the standard induction time, to characterize the
formation of aggregates.
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2. Experimentals
Silicon (100) wafers were supplied by University Wafers; all solvents were
bought from Sigma-Aldrich: hydrofluoric acid (HF) is 48% in water, tetrahy-
drofuran (THF) and toluene were of anhydrous grade, ethanol was ACS
reagent grade. (3-Aminopropyl)triethoxysilane (APTES) were bought from
Merck and used without further purification. BCAR were purchased from
different vendors (Sigma-Aldrich, Alfa Aesar with purity >97%) and, as soon
as received, its oxidation state was always checked with optical absorption
measurements to confirm the lack of detectable, already existing, oxidated
species.
Two type of PSi samples were prepared using the standard electrochemical
etching procedure: 1) nSi-0.02 Ωcm etched in 16% HF, 16% H2O and 84%
ethanol(v/v) at 82 mA/cm2 current density and 2) nSi-0.01 Ωcm etched in
5.5% HF in water added with 0.5% TritonX-100 at 53 mA/cm2 current den-
sity.
Four different PSi surfaces have been prepared:
A: as-prepared PSi: its surface is terminated with hydride species;
B: PSi treated with mild thermal oxidization: PSi A was placed on hot plate
at 200◦ for 4 h;
C: silanized PSi: PSi B was immersed in APTES (1% (v/v) solution in
toluene) and kept on an hot plate at 60◦ for 15 min. Then it was
thoroughly rinsed with ethanol;
D: wet oxidized PSi: PSi B was immersed in H2O2 (30% w/w) for 24 h.
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The mild oxidation conditions used in B samples were chosen to keep the
process compatible with highly nanoporous samples that own large specific
surface but tend to collapse into bulk silica upon high temperature treat-
ment. The further treatment (C and D) has been introduced to stabilize the
PSi surface (see discussion below).
The loading procedure depends on the type of experiment. In the immer-
sion method the drug was loaded by simply dipping the PSi sample for 24 h
into THF BCAR solution. The impregnation of porous samples was done by
subsequent release of some drops (few µL each) of the loading solution, until
the desired amount of BCAR was loaded onto the porous area, carefully con-
trolling the spread of each drop and avoiding the wetting of the non porous
region. Before depositing a new drop we waited for solvent evaporation.
Released BCAR has been quantified using a Varian Cary-100 spectropho-
tometer, using quartz cuvette and spectra were baseline corrected against
the same cuvette filled with solvent.
3. Results and Discussion
Since the BCAR has a limited solubility in many solvents, we dissolved it
in THF to prepare the initial, concentrated solutions used to load the sam-
ples. BCAR has been loaded into PSi with two methods: 1) immersion and
2) impregnation. We did not fragment the PSi layer into microparticles, as
it is usually done in DDS application, since the use of flat samples eases the
understanding of surface effects, such as aggregates formation.
Fig.1 reports the results obtained with the immersion method: PSi-2 A and
D are immersed in THF solutions with different BCAR concentrations; then
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the non-porous surface of each chip has been rinsed with THF before placing
the sample in THF. The amount of BCAR released is 5 to 20 times larger
than the equilibrium concentration of an homogeneous solution without phys-
ical adsorption (indicated by the green dotted line, details of calculation are
reported in the ESI). Neither the amount of BCAR entrapped, nor the SDs
depend on the state of the PSi surface as they present the same behaviour
both on as-prepared (hydrophobic) and on oxidized (hydrophilic) samples.
Since THF in an excellent solvent (BCAR solubility: 10 mg/mL), we as-
sume that BCAR is released quantitatively: on average, roughly 5 nmol of
BCAR have been loaded in each sample, i.e. about 10 µg/mgPSi that is an
order of magnitude smaller than the equilibrium amount reached by loading
hydrophilic drug into hydrophilic PSi [17]. The large SDs obtained (aver-
age value: 30%) can not be ascribed to non-specific adsorption, otherwise
similar SDs should have been obtained also from impregnation releases for
samples loaded with the same amount of BCAR (see data reported in Fig.2B:
PSi loaded with 3.8 mg using 0.3 mg/mL shows a SD of about 10%). This
comparison suggests that the high SDs of immersion experiments are due to
aggregates that form inside the pores, even if BCAR is loaded at concen-
trations lower than its solubility in THF. The large loading irreproducibility
obtained using the immersion method does not allow for precise delivery of
known amount of drugs, thus we investigated if impregnation method pro-
vides a better control.
We used THF solutions of BCAR at various concentrations to impregnate
each PSi-1 A samples with different amount of drug. PSi samples composi-
tions are summarized in Tab.1. During the loading, no macroaggregates form
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Figure 1: Quantity of released BCAR vs the estimated BCAR amount inside the pores at
equilibrium. Green dotted line is the bisector.
Table 1: Loading conditions of PSi-1 A samples.
BCAR loading loaded BCAR
sol. conc. [mg/mL] [µg]
1.5 3.8 7.5 10.5
0.3 3.8 7.5 10.5 12.0
0.17 6.8 10.2 13.6
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on PSi surface and the coffee-stain effect is limited. In fact, roughly 48% of
the BCAR was loaded in the 45% central area of the sample (details are
given in the ESI). Releases were monitored using ethanol as model solvent
(BCAR solubility is 0.03 mg/mL) as it slows down the kinetics, compared
to THF and it permits to follow the kinetics with sufficient accuracy.
As reported in Fig.2A-C, different kinetics were obtained depending both on
the amount of BCAR loaded and on the concentration of the loading so-
lution. Using the less concentrated solution (0.17 mg/mL, see Fig.2A) the
samples loaded with 6.8 and 10.2 µg of BCAR show nearly complete and
reproducible BCAR release (about 90±6%), while the sample containing the
largest amount of BCAR releases only about 60±20%. By increasing the
concentration of the loading solution from 0.17 mg/mL to 0.3 mg/mL (see
Fig.2B), a reduced recovery of BCAR occurs at smaller loading (together
with a corresponding increase of the SDs). With the most concentrated solu-
tion (1.5 mg/mL, see Fig.2C) only limited and poorly reproducible releases
of BCAR are achieved (55±18% on average), irrespectively from the loaded
amount. Moreover, during the experiments done on the samples highlighted
in Tab.1, macroscopic surface aggregates form, even if the BCAR final con-
centrations were from 6 to 23 times lower than its solubility in ethanol and
the release media were well stirred. The solubility of aggregates is slowed
down compared to BCAR in molecular form; in fact they take up to 35
hours to completely dissolve. We have no evidence of either their crystalline
or amorphous form, as the amount of material was too small to collect suffi-
cient X-ray signals.
The presence of aggregates and their role on the release kinetics is high-
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Figure 2: Normalised BCAR release profiles from PSi using loading solutions with BCAR
concentrations of A) 0.17 mg/mL, B) 0.3 mg/mL and C) 1.5 mg/mL. Panel D) reports
the release from PSi-1 A and D. Lines are guides to the eyes.
lighted by defining the following Figure-of-Merit: FOM = [µg] loaded BCAR
SD of release experiment
.
Large FOM indicates that BCAR release is quantitative and reproducible,
while small FOM points to partial and irreproducible recovery. Fig.3 re-
ports how FOM varies across all the dataset: when the 1.5 mg/mL loading
9
Figure 3: FOM as a function of the amount of loaded BCAR.
solution is used, it always assumes low values, while using the more diluted
solutions, the FOM value is low only for large amount of BCAR loaded and
it increases for smaller quantities.
This fact correlates with the macroaggregates formation on PSi surface: they
are clearly visible when only 3.8 µg of BCAR are loaded using 1.5 mg/mL,
while if 0.3 mg/mL is used, their formation is evident when at least 12 µg
of BCAR are loaded. A particular case is the sample loaded with 10.5 µg of
BCAR using the 0.3 mg/mL solution: its FOM has an intermediate value
of 8, the sample does not form visible aggregates, but it releases slightly
less BCAR, compared to the samples loaded with smaller BCAR amount
(about 80% vs 90%) and its SD is a bit larger (11% vs 6%). These consider-
ations suggest that, when using a 0.3 mg/mL solution, the limiting amount
of BCAR that can be loaded without macroaggregates formation is 10.5 µg.
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We did not observed significant difference when either PSi-1 A or D are
used (as reported in Fig.2D), thus our experiments suggest that the BCAR
nucleation-aggregation phenomenon is mainly ruled by the high PSi sur-
face energy due to nanostructuring, while it is weakly related to the actual
surface chemistry. Because of their stochastic length-scales, nanostructured
surfaces form nuclei with broad size distribution: the smallest being readily
re-dissolved, while the largest will live for significant time; in case of highly
insoluble drug, they live much longer than the typical rate of release. In turn,
such broad distribution reflects into broader range of kinetics, that are caught
by an increased SD during the experiments. We speculate that, during the
release, localized volumes at pore openings become sovrasaturated in BCAR
and that such concentration fluctuations are the driving force to induce the
formation of nuclei (crystallization driven by such effect have been already
demonstrated for proteins [18]).
The role the surface chemistry plays in BCAR HN has been investigate by
performing the experiments on the four different PSi surfaces. We found that
A,C and D samples loaded with 6 µg of BCAR (using 0.3 mg/mL solution)
release almost quantitatively the drug with SDs of about 6% (see Fig.4); on
the other hand B samples release only 59±7% of the loaded molecules. To
understand the fate of the missing BCAR, after the release in ethanol, the
B samples have been placed in THF, so that, if BCAR aggregates formed
within the pores, they would be readily dissolved. The facts that no BCAR
has been detected in THF and that the SDs are less than 10% suggest that
the smaller recovery from B is not due to nucleation-aggregation phenomena.
Since C and D samples released nearly completely the loaded BCAR, we be-
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Figure 4: Normalised BCAR release profiles from PSi-1 A (green-circles), PSi-1 B (black-
crosses) PSi-1 C (red-triangles) and PSi-1 D (blue-squares); lines are guides to the eyes.
lieve that low temperature oxide alone is not a stable surface and it is able to
degrade large amount of BCAR within short time (few hours). This fact is
quite surprising, as A samples are generally thought to be more reactive than
B ones. A simple immersion of the low temperature samples in peroxides or
the APTES silanization is sufficient to stabilize PSi, albeit on the short time
scale of load-and-release experiments. In fact, the BCAR long term stability
is limited in all the PSi samples: we impregnated PSi-1 A and C and we
performed the release in THF after two weeks, during which the samples were
stored in the dark and at room temperature; the amount of BCAR recovered
were 15±4% and 40±7%, respectively. The low BCAR stability might be the
result of autooxidation reactions, as reported in [19] and we speculate that
reactive species (possibly radicals) and/or defects present on the surface of
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the low temperature oxides allow tunneling of electrons from BCAR to the
semiconductor, speeding up the degradation of the drug.
4. Conclusions
By discussing the role of HN on nanoporous materials used as DDS for
hydrophobic molecules, we underline two main limits of these class of DDS.
The first point to be carefully controlled is the capability of the carrier to
effectively store and protect the compounds over reasonably long time scale:
the simple load-and-release experiment does not show the (possible strong)
cargo degradation induced by slow chemical reactions.
The second limit is the negligible amount of drug that can be loaded (irre-
spective from the state of the surface) without the formation of macroscopic
surface aggregates during the release in not-so-good solvents (e.g. in bio-
logical relevant environments). The presence of aggregates was detected by
a reduced amount of BCAR released and by a corresponding SDs increase.
Such aggregates form even if drug concentration is well below the solubility
limit and we suppose that nucleation events happens nearby pore openings
due to localized sovrasaturated BCAR regions. The dissolution rate of these
aggregates is highly variable and much slower than the rate at which molecu-
lar BCAR is released from PSi under same conditions. The poorly controlled
aggregation degrades the reproducibility of the experiments, thus the deliv-
ery of hydrophobic molecules from nanoporous carriers needs to find a the
trade-off between the amount of loaded drug and the release reproducibility.
We suggest the use of such experiments to check for HN events on nanostruc-
tured surfaces as an alternative to the standard induction time method. Our
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approach shows several important advantages as it does not rely on visual
inspection of the samples and is able to detect solid nuclei well before they
reach the -generally considered- micron-size regime. Compared to the induc-
tion time, this method provides an average response over the entire sample
surface on a much shorter time and pave the way to more in depth studies
about surface driven HN.
5. Supplementary Information
5.1. Amount of β-carotene loaded with the immersion method
To calculate the amount of β-carotene (BCAR) loaded into porous silicon
(PSi) samples at equilibrium, both the BCAR concentration in the loading
solutions and the empty volume of the Psi samples should be known.
The samples were loaded by submerging them in 1.5 mL of BCAR solutions
in tetrahydrofuran (THF) at known concentrations for 24 h (0.32, 0.38, 0.77,
0.88, 1.60, 2.80 and 3.22 mg/mL for PSi-2 A; 0.32, 0.38, 0.77, 0.88, 1.89,
2.80 and 3.76 mg/mL for PSi-2 D.
The empty volume in each Psi chip is about 25 µL, as estimated from the
porous area (A=0.28 cm2), the layer thickness and its porosity.
The thickness (d=16 µm) and the refractive index (n=2) of PSi-2 samples
were obtained from SEM cross section and optical interferometry. Once
these two parameters are known, the layer porosity (55%) was estimated via
Bruggeman approximation:
f · n
2
b − n2
n2b + 2n
2
+ (1− f) · n
2
a − n2
n2a + 2n
2
= 0
where f indicates the fraction of silicon in the porous layer, na and nb the
air and silicon refractive index (in the IR region na=1 and nb=3.4).
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Figure 5: Schematic of PSi internal and external areas.
5.2. Coffee-stain effect in the impregnation method
Since the impregnation method requires the sequential deposition of some
liquid drops on the PSi surface, we might expect the formation of coffe-stain
on the edge of the porous area. To evaluate it, we loaded a PSi-1 A sample
and we cleaved it along the blue dotted lines sketched in Fig.5. Then we
performed the BCAR release in THF both from the external part (55% of
the total area, orange area in Fig.5) and from the internal one (45% of the
total area, yellow area in Fig.5). We estimated a negligible effect of the
coffee-stain since 52% of the BCAR was released from the external area and
48% from the internal one.
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